Allspring Global Investments Holdings LLC Trims Holdings in USANA Health Sciences, Inc. (NYSE:USNA)

Allspring Global Investments Holdings LLC reduced its position in USANA Health Sciences, Inc. (NYSE:USNA) by 60.8% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 13,906 shares of the company’s stock after selling 21,541 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in USANA Health Sciences were worth $745,000 as of its most recent filing with the SEC.

Several other institutional investors also recently bought and sold shares of USNA. SG Americas Securities LLC acquired a new position in USANA Health Sciences in the 3rd quarter valued at $581,000. Denali Advisors LLC increased its stake in USANA Health Sciences by 16.9% in the 3rd quarter. Denali Advisors LLC now owns 47,129 shares of the company’s stock valued at $2,762,000 after buying an additional 6,800 shares during the period. Robeco Institutional Asset Management B.V. increased its stake in USANA Health Sciences by 27.0% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 23,819 shares of the company’s stock valued at $1,396,000 after buying an additional 5,064 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in USANA Health Sciences by 60.6% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,376 shares of the company’s stock valued at $198,000 after buying an additional 1,274 shares during the period. Finally, Strs Ohio increased its stake in USANA Health Sciences by 4.8% in the 3rd quarter. Strs Ohio now owns 10,900 shares of the company’s stock valued at $638,000 after buying an additional 500 shares during the period. 54.25% of the stock is owned by institutional investors and hedge funds.

Insider Activity at USANA Health Sciences

In related news, insider Robert A. Sinnott sold 3,945 shares of the stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $46.55, for a total value of $183,639.75. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other USANA Health Sciences news, COO Walter Noot sold 5,240 shares of the firm’s stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $49.05, for a total transaction of $257,022.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Robert A. Sinnott sold 3,945 shares of the firm’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $46.55, for a total transaction of $183,639.75. The disclosure for this sale can be found here. In the last three months, insiders have sold 24,807 shares of company stock valued at $1,200,791. Insiders own 0.33% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the stock. DA Davidson lowered their price target on shares of USANA Health Sciences from $53.00 to $48.00 and set a “neutral” rating on the stock in a research note on Thursday, February 22nd. StockNews.com raised shares of USANA Health Sciences from a “buy” rating to a “strong-buy” rating in a research note on Friday, January 12th.

USANA Health Sciences Stock Down 2.4 %

NYSE:USNA opened at $43.66 on Thursday. USANA Health Sciences, Inc. has a fifty-two week low of $42.59 and a fifty-two week high of $69.60. The stock has a market cap of $840.02 million, a PE ratio of 13.23, a price-to-earnings-growth ratio of 1.35 and a beta of 0.91. The firm’s fifty day simple moving average is $47.42 and its 200-day simple moving average is $48.96.

USANA Health Sciences (NYSE:USNA) last issued its quarterly earnings data on Tuesday, February 6th. The company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.52 by $0.35. The firm had revenue of $221.08 million for the quarter, compared to analysts’ expectations of $206.70 million. USANA Health Sciences had a net margin of 6.93% and a return on equity of 13.49%. Equities analysts anticipate that USANA Health Sciences, Inc. will post 2.73 earnings per share for the current year.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.